Antihistamines Fail to Relieve Eczema Symptoms

Published Date: 31 Jul 2026

Oral antihistamines added to standard atopic dermatitis treatment result in detectable but clinically unimportant reductions in eczema severity and itch and may cause cognitive impairment.

Read Full News

Latest News

Two Symptoms Linked to Antibiotic Delays in Presumed Sepsis

— GI and respiratory symptoms at presentation both flagged in observational study

Exercise and Cancer Survival; COVID Vaccine and Immune Checkpoint Inhibitors

— Also in TTHealthWatch: colonoscopy after polyp removal

BPAP Intervention Flops in Asthma Study

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

To Face Scrutiny at ESC: Statins for the Elderly, New Heart Attack Therapies

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

Radio Silence on Mitch McConnell's Health Persists

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

The danger may be in the dosing, not in the drug itself

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

— GI and respiratory symptoms at presentation both flagged in observational study

— Also in TTHealthWatch: colonoscopy after polyp removal

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

The danger may be in the dosing, not in the drug itself

News All Time

Discordant Tissue Findings in Suspected HLH

Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome characterized by an exaggerated immune response to a triggering stimulus.

What Extreme Athletes Teach Us About Sleep Deprivation

What can a 1000-mile race teach MDs about sleep? Dr Alison Kole shares sleep deprivation insights from ultramarathon racing and gives practical tips for exhausted patients.

Omalizumab May Ease Inflammation in Chronic Urticaria

In patients with antihistamine-resistant chronic spontaneous urticaria, omalizumab treatment is linked to clinical improvement and reduced systemic inflammatory markers and D-dimer levels.

Pediatric Lung Transplantation Enters a New Era

New CFTR modulators are reshaping pediatric lung transplantation, forcing clinicians to rethink when children should be referred and listed.

CVS Health's Aetna to Streamline Cancer Treatment Approvals

CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment ⁠for cancer patients to only one medical prior authorization...

Diphtheria Debate Exposes Health Misinformation

A diphtheria death in Sicily has reignited debate over vaccines, migration, and how political spin can distort public health facts.

Azithromycin Use Cuts Cesarean Infections

Azithromycin has been shown to lower the risk for postoperative infection during cesarean deliveries when added to more standard prophylactics such as cefazolin.

Methotrexate for IBD: How Do GIs Use It?

A new study offers the most comprehensive real-world look yet at methotrexate use in treating IBD in everyday practice.

AI Digital Twins Get Better and Better: Cancer in Crosshairs

Digital twins allow doctors to simulate treatment to see what will work best — and the tech has made real strides in cardiology. Oncology remains the bigger challenge.

S1P Modulators: 5 Agents, One Safety Playbook

Five S1P modulators now span neurology and GI. Bruce Cree, MD, PhD, and others weigh in on why selectivity differences are no longer academic.

As-Needed Allergic Rhinitis Meds Comparable to Daily Use

Patients with allergic rhinitis who use medication as needed can achieve symptom control and treatment satisfaction comparable to those achieved by patients who use them daily.

Host-Directed Therapies and Phages in Lung Care

Host-directed and phage therapies are emerging as alternatives to antibiotics in managing lung infections in a worsening antimicrobial resistance crisis.

Mild Brain Injury Frequently Missed in the ED

Only 21% of adults with closed head injury have mTBI diagnosed or clinically suspected in the ED, despite 41% meeting diagnostic criteria, with missed diagnoses most common among middle-aged adults.

D10 Matches D50 for Hypoglycemia, Shows Lower Rebound Risk

A lower-concentration dextrose solution matches the standard treatment for hypoglycemia in the emergency department but carries a lower risk for rebound hypoglycemia.

A Rare Hearing Implant Bypasses Damaged Nerves

When cochlear implants failed, doctors turned to a brainstem auditory implant to restore sound awareness in a patient with profound deafness.

Two-Midnight Rule: Key Strategies for Observation Patients

The Two-Midnight Rule has created important clinical and operational strategies for hospitals.

Recommended News For You

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Climate change is expected to increase the number of suicide deaths

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

The diamonds that could find cancer

NIH research cuts leave cancer patient facing hard choice

Scientists call into question safety of potential new anticancer treatment

Recommended Articles For You

Understanding Fibrosarcoma: What You Need to Know  

Preventing Venous Thromboembolism During Hematologic Cancer Care 

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts 

Precision Oncology Using Tumor Evolutionary Trajectory Modeling 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Herpes virus-based vaccine shows promise in targeting tumors without side effects

2.

Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia

3.

Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.

4.

The combination of nitedanib and prednisone reduces exacerbations of pulmonary diseases in radiative pneumonitis

5.

Gedatolisib Combo Approved for Advanced Breast Cancer

1.

New Research on Craniopharyngioma 

2.

Uncovering New Hope for Follicular Lymphoma Patients

3.

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice

4.

Molecular Mechanisms of Chromatin Condensation During Persistent Cellular Stress

5.

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

3.

Managing Fatigue During Cancer Treatment

4.

Navigating the Complexities of Ph Negative ALL - Part VIII

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot